To Evaluate the Safety and Tolerability of Carbognilumab Combined With Chemotherapy as the First-line Treatment for Patients With KEAP1 Mutated Advanced or Postoperative Recurrent Non-small Cell Lung Cancer (NSCLC)
Clinical trial NCT06341660 · UNKNOWN
Trial details
- NCT number
- NCT06341660
- Sponsor
- Guangzhou Institute of Respiratory Disease
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-05-25
- Primary completion
- 2025-06-01
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.